...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >A prospective randomized trial on azathioprine addition to cyclosporine versus cyclosporine monotherapy at steroid withdrawal, 6 months after renal transplantation.
【24h】

A prospective randomized trial on azathioprine addition to cyclosporine versus cyclosporine monotherapy at steroid withdrawal, 6 months after renal transplantation.

机译:肾移植后6个月,在类固醇戒断时,将硫唑嘌呤与环孢霉素与环孢素单药联合应用的一项前瞻性随机试验。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Many attempts have been made to withdraw steroid therapy in renal transplant patients in order to avoid its many side effects. Results have been, so far, controversial. In this randomized prospective study, we compare the efficacy of azathioprine adjuncts to cyclosporine at the time of steroid withdrawal, 6 months after transplantation, versus Cyclosporine monotherapy, in preventing acute rejection. METHODS: One hundred and sixteen kidney transplant patients with good and stable renal function (creatininemia <2 mg/dl) received, in the first 6 months, cyclosporine + steroid. They were then randomized into two groups (A and B), and steroid therapy was withdrawn over 2 months. Group A (58 patients) continued on cyclosporine monotherapy, whereas group B (58 patients) added azathioprine (1 mg/kg/day) at the beginning of randomization and continued on cyclosporine + azathioprine. In both groups, patients resumed steroid therapy at the first episode of acute rejection. Follow-up after randomization was 5.3+/-1.6 years. RESULTS: After 5 years, the incidence of steroid resumption was 57% in group A and 29% in group B (P<0.02); of those, 68% and 88% of them were within 6 months from randomization. Anti-rejection therapy was always successful. Five-year patient and graft survival rates were 90% and 88% in group A and 100% and 91% in group B. Creatininemia did not differ, at follow-up. Side effects differed only for mild and reversible leukopenia caused by azathioprine in group B. CONCLUSION: Cyclosporine plus azathioprine is more effective than cyclosporine monotherapy in reducing the incidence of acute rejection after steroid withdrawal. Graft loss as a result of chronic rejection, mild in both groups, did not differ. Steroid withdrawal is feasible and advantageous, and the addition of azathioprine allowed 71% of our selected patients to remain steroid-free.
机译:背景:为避免肾移植患者的许多副作用,已作了许多尝试撤回类固醇治疗的尝试。迄今为止,结果一直存在争议。在这项随机前瞻性研究中,我们比较了在移植后6个月停用类固醇时硫唑嘌呤佐剂与环孢素的疗效,与环孢素单一疗法相比,在预防急性排斥反应方面的疗效。方法:116名肾功能良好且稳定的肾移植患者(肌酐水平<2 mg / dl)在头6个月接受了环孢素+类固醇治疗。然后将他们随机分为两组(A和B),并在2个月内停用类固醇疗法。 A组(58例患者)继续使用环孢素单药治疗,而B组(58例患者)在随机分组开始时添加硫唑嘌呤(1 mg / kg /天),并继续使用环孢素+硫唑嘌呤。两组患者均在急性排斥反应的第一发作时恢复类固醇治疗。随机分组后的随访时间为5.3 +/- 1.6年。结果:5年后,A组类固醇恢复的发生率为57%,B组为29%(P <0.02);其中,分别有68%和88%在随机化后的6个月内。抗排斥疗法总是成功的。 A组的五年患者和移植物存活率分别为90%和88%,B组为100%和91%。随访时肌酐水平无差异。 B组仅由硫唑嘌呤引起的轻度和可逆性白细胞减少症的副作用有所不同。结论:环孢霉素加硫唑嘌呤比环孢素单药治疗在类固醇戒断后降低急性排斥反应的发生率更有效。两组由于轻度慢性排斥反应导致的移植物损失没有差异。类固醇戒断是可行和有利的,添加硫唑嘌呤可使我们选择的患者中有71%保持无类固醇。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号